Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.15p +0.58% 26.00p 25.55p 26.45p 26.45p 25.25p 25.55p 268,296 16:28:33
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -33.2 -14.1 - 77.13

Motif Bio Share Discussion Threads

Showing 2551 to 2574 of 2575 messages
Chat Pages: 103  102  101  100  99  98  97  96  95  94  93  92  Older
DateSubjectAuthorDiscuss
11/12/2018
16:36
They may be waiting for FDA approval then If someone wants to buy world wide distribution rights they with put in for EMA submission,
barriew
11/12/2018
09:27
Where is the EMA submission, how can it take more than 6 months following the FDA submission? I know it's not a cut and paste excersise, but come on 6 months ffs
return_of_the_apeman
08/12/2018
10:40
Mike they should rise before the FDA decision before the 13th February. No one can guess share prices but it’s looking cheap at the moment.
barriew
08/12/2018
10:40
Mike they should rise before the FDA decision before the 13th February. No one can guess share prices but it’s looking cheap at the moment.
barriew
07/12/2018
23:25
Na let them grow
1fraser
07/12/2018
14:08
I bought some at 40p & 32p mike1608 but it has always been a speculative hold. The share price is just marked down on the market falls in an unsupported limbo position until we gain outcomes in spring 2019. I felt the evidential work within the submission was conducted diligently and keep the faith. If it gets approval we will see a substantial share price spike if not it will become another summit/IMM. GL whatever you decide
catch007
07/12/2018
12:40
I bought shares of an average of 30p per share. Should I cut loses?
mike1608
06/12/2018
13:40
Everything is down regardless, just vrs having a good day for me. Not long until February
barriew
06/12/2018
12:30
Time to accumulate!
l4z4rus
03/12/2018
12:14
It’s a waiting game, the hard part was getting the trials finished and the great results , within 10% of vancomycin. Now it’s just hold your nerve until the FDA report. Some would rather cut losses and invest elsewhere, other will accumulate. Others will try and talk the price down and run a short position. Everyone to their own. To me everything is positive at the moment, upon FDA acceptance or refusal we can only sit and wait. It’s not like imm which was talked up by the board and this BB only to crash from a badly run trial.
barriew
28/11/2018
12:55
Agreed, with small caps charting is of very limited use. The price will be driven by newsflow and fundamentals in the medium to long term.
bountyhunter
28/11/2018
10:32
The price was lower than this last year. Furthermore I would believe most here will be investing on fundamentals opposed to technicals. Whilst its frustrating for the price to drop below recent support I don't believe this has any implications regards the fundamentals as previously alluded.
rabito79
28/11/2018
09:08
Price dropped below 28 for the first time. Sold out. Let the trend be your friend. Good luck to those holding.
uncleoswald
27/11/2018
18:09
Investors get nervous when there is no news flow. Add to this recent examples of Summit & IMM and many others the risk of failure and losses takes hold. I lost heavily on IMM however I do believe the MTFB has carefully delivered what it said it would throughout this approval process and has been meticulous in data collection, analysis, presentation and into formal submission. The company has provided due dates for outcomes and given the volume of data it would be highly unlikely to get indicative response at this juncture. Global indices have all shown significant weakness and the MTFB share price has also fallen back significantly. I am a holder rather than a buyer at present however it remains highly speculative I wholly agree with gclark and I believe (and hope) the data is vindicated with an approval.
catch007
27/11/2018
09:23
Maybe. I have looked at the volume and it is pretty low. Investors may want the money for what they regard is a better short term prospect. I have sold some mtfb and amphion in the past for that reason. But I've just bought a little more mtfb. The clinical evidence looks good to me. I was wrong about summit but that was about an ongoing clinical trial which has a lot of unknowns. In this case the data is there. But everything is a risk!
gclark
27/11/2018
08:12
The share graph does not look good. With 3 months to go til approval by the FDA for a new antibiotic, you would expect the share price to be hitting new highs. Instead, it is hitting new lows. Conclusion you have to draw is someone knows it is not going to get approval. Can’t think of any other logical reason. If that is the case, price will continue dropping!
uncleoswald
26/11/2018
16:12
Why is this going down further?
philoosh
20/11/2018
13:50
Thought they would have lined up a distribution partner by now or at least a short list of contenders. If Motif have hired Ms May to negotiate this deal, then investors will have to endure a double stab in the back?
hoggar
20/11/2018
12:56
Even more nervously now......
philoosh
09/11/2018
14:59
For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.
spmc
07/11/2018
18:28
https://www.theguardian.com/society/2018/nov/07/antibiotic-resistant-superbugs-will-kill-90000-britons-by-2050
small crow
30/10/2018
09:11
Very nervously now !!!!
philoosh
24/10/2018
12:04
Safe to say this is the most frustrating share i've ever owned. Fingers crossed we see some movement DEC or early JAN.
t-trader
17/10/2018
11:09
I'm holding, nervously.....
philoosh
Chat Pages: 103  102  101  100  99  98  97  96  95  94  93  92  Older
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181212 02:46:35